Study Reveals Inconsistent Wait Times for Decisions on Cancer Drug Coverage
October 27th 2023The mean lag time between FDA approval and insurance coverage for 89 cancer drugs ranged from 2.3 months to 8.2 months. But cancer drugs approved more recently were more likely to have shorter coverage lags.
Read More
Positive Results for Pairing Flu, COVID-19 Vaccination
October 16th 2023Coadministration of flu and COVID-19 vaccines is safe and effective, according to findings published recently in JAMA Network Open, and Moderna report a strong immune response to its experimental vaccine that would combine flu and COVID-19 vaccination into a single shot.
Read More
Trial Investigates Weight Loss Drug for Patients with Heart Failure
October 6th 2023Patients with heart failure and obesity who were administered semaglutide experienced better results — they reported fewer symptoms, felt less physically limited, lost more weight, and could walk longer in a 6-minute test.
Read More
Phentermine/Topiramate More Cost-Effective than Semaglutide for Teen Obesity
September 15th 2023This simulation study also showed that semaglutide was the most effective for weight loss, and researchers said, long-term, savings associated with potential lifelong health improvements may shift the balance of cost-effectiveness.
Read More
Switching to Long-Acting Injectable Paliperidone is Not Cost-Effective in Stable Schizophrenia
August 25th 2023Long-acting injection formulations of paliperidone improve health outcomes in adults with schizophrenia but that might not be enough to offset their substantial costs, new study finds.
Read More
Early Depression Unlikely To Cause More Severe Disability in MS patients, Study Suggests
July 17th 2023Researchers have been working on sorting out the causal direction of multiple sclerosis (MS) and depression. These findings suggest that depression can be a consequences of MS-related disability not the other way around.
Read More
Study Shows Stopping Disease-Modifying Therapy May Be Safe for Older Adults with MS
July 5th 2023The researchers conclude that it is “reasonable option” for older patients with stable multiple sclerosis (MS) to stop taking disease-modifying therapy because the risk of relapse from doing so is small.
Read More
FDA Accepts BLA for Lifileucel for Difficult-to-Treat Melanoma
May 31st 2023Lifileucel is a polyclonal tumor infiltrating lymphocyte (TIL) therapy designed for patients with advanced melanoma who have experienced progression after previous treatment with anti-PD-1/L1 therapy and targeted therapy.
Read More
FDA Approves New Treatments for Opioid Overdose, Opioid Use Disorder
May 24th 2023The FDA recently approved Brixadi to treat moderate to severe opioid use disorder in patients who have already started treatment with a transmucosal form of buprenorphine, and have approved Opvee as an emergency treatment to reverse known or suspected opioid overdose in people ages 12 years and older.
Read More
But higher costs for cancer drugs did not influence some common measures of adherence, such as medication possession ratio and proportion of days. The researchers believe that cancer patients may be more likely to adhere to medication regimen, regardless of price, because the drugs are critical for survival.
Read More